FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4311334533> ?p ?o ?g. }

• W4311334533 endingPage "S147" @default.
• W4311334533 startingPage "S147" @default.
• W4311334533 abstract "Sotrovimab is a monoclonal antibody approved in Europe for the treatment of adults and adolescents (age ≥12 years) with COVID-19 who do not require oxygen supplementation and are at increased risk of progressing to severe COVID-19. We assessed the cost-effectiveness of sotrovimab versus standard of care (SOC) as an outpatient treatment for patients (aged ≥18 years, in line with the pivotal COMET-ICE trial) in Italy with mild-to-moderate COVID-19 at high risk of disease progression. A Markov cohort model with Discretely Integrated Condition Event simulation followed a cohort of 1,000 patients in 5-year, 10-year and lifetime (100 years) time horizons from an Italian National Health Service perspective. At model development, SOC consisted of treatments such as antipyretics. As sotrovimab was an add-on to SOC, no treatment-related cost was allocated to SOC. Sotrovimab’s treatment effect was obtained from the COMET-ICE trial, which showed a 79% relative risk reduction of all-cause hospitalizations ≥24 hours or death from any cause within 29 days of randomization. Cost, resource use and quality-of-life inputs were obtained from published literature and national/regional tariffs. The model was internally and externally validated. The sotrovimab cohort was associated with 5-year, 10-year and lifetime quality adjusted life-year (QALY) gains of 143.66, 235.00 and 346.87, respectively, with increased lifetime direct healthcare costs of €2,537,956. Incremental cost-effectiveness ratios versus SOC were €17,667 (5-year), €10,800 (10-year) and €7,317 (lifetime) per QALY. Deterministic sensitivity analysis found that hospitalization rate and treatment cost had the largest impact on the ICER. In probabilistic sensitivity analysis, sotrovimab was cost-effective in 100% of iterations based on a willingness-to-pay threshold of €15,000 per QALY gained. Sotrovimab was found to be cost-effective versus SOC for early treatment of high-risk patients with COVID-19 in Italy. Funding: GSK (Study 215021) / Vir Biotechnology" @default.
• W4311334533 created "2022-12-25" @default.
• W4311334533 creator A5020772963 @default.
• W4311334533 creator A5030199881 @default.
• W4311334533 creator A5071587383 @default.
• W4311334533 creator A5076889225 @default.
• W4311334533 creator A5087454592 @default.
• W4311334533 date "2022-12-01" @default.
• W4311334533 modified "2023-10-03" @default.
• W4311334533 title "EE465 Cost-Effectiveness of Sotrovimab for the Treatment of Mild-to-Moderate COVID-19 in Patients at High Risk of Disease Progression in Italy" @default.
• W4311334533 doi "https://doi.org/10.1016/j.jval.2022.09.710" @default.
• W4311334533 hasPublicationYear "2022" @default.
• W4311334533 type Work @default.
• W4311334533 citedByCount "0" @default.
• W4311334533 crossrefType "journal-article" @default.
• W4311334533 hasAuthorship W4311334533A5020772963 @default.
• W4311334533 hasAuthorship W4311334533A5030199881 @default.
• W4311334533 hasAuthorship W4311334533A5071587383 @default.
• W4311334533 hasAuthorship W4311334533A5076889225 @default.
• W4311334533 hasAuthorship W4311334533A5087454592 @default.
• W4311334533 hasBestOaLocation W43113345331 @default.
• W4311334533 hasConcept C112930515 @default.
• W4311334533 hasConcept C126322002 @default.
• W4311334533 hasConcept C159110408 @default.
• W4311334533 hasConcept C194828623 @default.
• W4311334533 hasConcept C2779951463 @default.
• W4311334533 hasConcept C3019080777 @default.
• W4311334533 hasConcept C44249647 @default.
• W4311334533 hasConcept C64332521 @default.
• W4311334533 hasConcept C71924100 @default.
• W4311334533 hasConcept C72563966 @default.
• W4311334533 hasConcept C82789193 @default.
• W4311334533 hasConceptScore W4311334533C112930515 @default.
• W4311334533 hasConceptScore W4311334533C126322002 @default.
• W4311334533 hasConceptScore W4311334533C159110408 @default.
• W4311334533 hasConceptScore W4311334533C194828623 @default.
• W4311334533 hasConceptScore W4311334533C2779951463 @default.
• W4311334533 hasConceptScore W4311334533C3019080777 @default.
• W4311334533 hasConceptScore W4311334533C44249647 @default.
• W4311334533 hasConceptScore W4311334533C64332521 @default.
• W4311334533 hasConceptScore W4311334533C71924100 @default.
• W4311334533 hasConceptScore W4311334533C72563966 @default.
• W4311334533 hasConceptScore W4311334533C82789193 @default.
• W4311334533 hasIssue "12" @default.
• W4311334533 hasLocation W43113345331 @default.
• W4311334533 hasLocation W43113345332 @default.
• W4311334533 hasOpenAccess W4311334533 @default.
• W4311334533 hasPrimaryLocation W43113345331 @default.
• W4311334533 hasRelatedWork W1565078889 @default.
• W4311334533 hasRelatedWork W2016983880 @default.
• W4311334533 hasRelatedWork W2053130570 @default.
• W4311334533 hasRelatedWork W2055983460 @default.
• W4311334533 hasRelatedWork W2091852217 @default.
• W4311334533 hasRelatedWork W2116215834 @default.
• W4311334533 hasRelatedWork W2310170993 @default.
• W4311334533 hasRelatedWork W2603773853 @default.
• W4311334533 hasRelatedWork W2886888278 @default.
• W4311334533 hasRelatedWork W4283652125 @default.
• W4311334533 hasVolume "25" @default.
• W4311334533 isParatext "false" @default.
• W4311334533 isRetracted "false" @default.
• W4311334533 workType "article" @default.